- 1 Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2
- 2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label
- 3 phase 2/3 clinical study in Japan
- 5 Keishi Kido<sup>1</sup>, Kayo Ibaragi<sup>1</sup>, Mitsuyoshi Tanishima<sup>1</sup>, Yosuke Muramoto<sup>1</sup>, Shun Nakayama<sup>1</sup>, Kohei
- 6 Ata<sup>1</sup>, Kenshi Hayashida<sup>1</sup>, Hideki Nakamura<sup>1</sup>, Yasuhiko Shinmura<sup>1</sup>, Yoshiaki Oda<sup>1</sup>, Masafumi Endo<sup>1</sup>,
- 7 Kengo Sonoda<sup>1</sup>, Yuji Sasagawa<sup>2</sup>, Yasuhiro Iwama<sup>2</sup>, Kohji Ueda<sup>3</sup>, Takayuki Matsumoto<sup>1</sup>
- 8 <sup>1</sup>KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
- 9 <sup>2</sup>Meiji Seika Pharma Co., Ltd., Tokyo, Japan
- 10 <sup>3</sup>Professor emeritus, Kyushu University, Fukuoka, Japan
- 12 **CORRESPONDENCE**
- 13 Keishi Kido

11

16

- 14 KM Biologics Co., Ltd (KM Biologics), 869-1298 Kumamoto, Japan.
- 15 Email: kido@kmbiologics.com

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Abstract: Background: In the prolonged COVID-19 pandemic, there remains a high need for the development of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine that can be used more safely and effectively to prevents the disease onset or severe disease. To satisfy such unmet need, we are currently developing the inactivated whole particle SARS-CoV-2 vaccine (KD-414) and conducted a phase 2/3 study in healthy adults in Japan to accumulate more immunogenicity and safety data of KD-414 using the dose selected based on the results of the phase 1/2 study. **Methods:** In an open-label uncontrolled phase 2/3 study, adults aged 18 years or older without a history of COVID-19 or COVID-19 vaccination received two intramuscular doses of KD-414 at a 28-day intervals, followed by one intramuscular dose 13 weeks after the second dose as the primary immunization. Safety data were collected after the first dose of KD-414 in all participants to evaluate the safety profile. In predetermined immunogenicity analysis subjects, the neutralizing antibody titers against the pseudovirus SARS-CoV-2 (Wuhan) before the first vaccination and after each vaccination with KD-414 were evaluated. **Results:** A total of 2500 adults aged 18 years or older were enrolled; 2474 of them received the vaccination up to the second dose, and 2081 completed the third vaccination. Regarding the safety, no deaths or serious adverse reactions were recorded from the first vaccination until 28 days after the third vaccination with KD-414. The incidence of adverse reactions (number of participants with onsets/number of participants in the safety analysis set) was 80.6% (2015/2500). Adverse reactions

with an incidence of 10% or more included injection site pain, malaise, headache,

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

injection site erythema, myalgia, and injection site induration. A total of 11 events of grade 3 or higher adverse reactions that prevented daily activities in 9 participants. There was no increasing tendency in the incidence of adverse reactions responding to the vaccinations. To evaluate immunogenicity, 295 first comers enrolled from five age ranges were allocated to the immunogenicity analysis subjects; 291 participants received the vaccination up to the second dose, and 249 participants completed the third vaccination. The geometric mean titers (95% confidence interval [CI]) of neutralizing antibody titers against pseudovirus SARS-CoV-2 (Wuhan) 28 days after the second vaccination and 28 days after the third vaccination with KD-414 were 139.6 (118.9 - 164.0) and 285.6 (244.3 - 334.0), respectively, showing an approximately two-fold increase after the third vaccination compared to that after the second vaccination. The geometric mean titers (95% CI) of neutralizing antibody titers after the third vaccination were 327.6 (269.8 – 397.9), 272.2 (211.5 - 350.4) and 128.0 (51.6 - 317.7) in participants aged 18 to 40 years, 41 to 64 years, and 65 years or older, respectively, showing an age-dependency. Conclusion: This study confirmed the favorable safety profile of KD-414 as a result of three vaccinations of KD-414 administered to over 2000 healthy Japanese participants aged 18 years or older. There were no particular differences in the types and incidences of adverse reactions between vaccinations, and no tendency of an increase in adverse reactions with an increase in the number of vaccinations. Similar to the phase 1/2 study, neutralizing antibody responses appeared to be age-dependent and the highest titers were observed in the age group of 18 - 40 years. A phase 3 study in adults aged 18 - 40 years (¡RCT2031210679) and a phase 2/3 study in children aged

6 months - 18 years (jRCT2031220032) are currently ongoing. 64

Introduction

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was identified in December 2019 in Wuhan, Hubei Province, China. Thereafter, a Public Health Emergency of International Concern (PHEIC) was declared by the World Health Organization (WHO) on January 30, 2020 and a global pandemic was declared on March 11, 2020 1. As of September 9, 2022, 610 million cases of SARS-CoV-2 infection have been reported, resulting in 6.5 million deaths, so vaccine development against COVID-19 remains a significant global challenge 2. At present, vaccines against COVID-19, including inactivated vaccines, DNA vaccines and mRNA vaccines, viral vector vaccines, recombinant protein vaccines, etc. have been developed in the United States, the United Kingdom, China, and other countries around the world. In Japan, five products of mRNA vaccines, a viral vector vaccine, and a recombinant protein vaccine have been approved as of September 2022 3-7. However, most of them are imported and there are concerns regarding adverse reactions associated with new modality, such as myocarditis and thrombosis with thrombocytopenia syndrome 8-11. Because of that, booster shots (a third dose and fourth dose) and primary vaccination in children who require higher safety are not progressing. It is important to secure sufficient amounts of vaccines against SARS-CoV-2 in Japan for future emergencies and, similar to seasonal influenza vaccines, these vaccines will be continuously required in the future. Thus, domestic vaccines with an effectiveness and high safety are needed. KD-414 is a purified, inactivated, whole-virus SARS-CoV-2 vaccine, which is a modality that has been effective as multiple infectious disease vaccines and has an established safety. The manufacturing method is described in a previous report <sup>12</sup>. In the phase 1/2 study of KD-414, safety and immunogenicity were evaluated after two intramuscular vaccinations at three different doses of KD-414 which have different active ingredients (converted to protein amount): product L (2.5 μg/dose), product M (5 μg/dose), and product H (10 μg/dose). The results showed that the investigational product was well tolerated at all the dose levels, and the

neutralizing antibody titer was the highest in the product H (10 µg/dose) group <sup>12</sup>. Therefore, we

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Trial procedure

decided to use product H (10 µg/dose) in the late-stage clinical studies of KD-414. However, although the preventive effect of the novel corona vaccine against the onset has been shown to correlate highly with the neutralizing antibody levels 13, the threshold of neutralizing antibody titers required for prevention has not yet been established. Therefore, it is important to evaluate the vaccination regimen of the three doses as a primary series that can induce higher neutralizing antibody titers. Here, we report safety and immunogenicity findings from the phase 2/3 study conducted to evaluate the safety and immunogenicity of three doses of KD-414 in adults aged 18 years or older to accumulate more safety and immunogenicity data of KD-414 using the dose selected in the phase 1/2 study. Materials and Methods: Study design, and participants This multicenter, open-label, and uncontrolled study was conducted at 12 sites in Japan. The target number of participants was 2000, with healthy Japanese participants aged 18 years or older. The study excluded participants with a history of COVID-19 or vaccination against COVID-19, including unapproved vaccines. In addition, participants confirmed to be infected with SARS-CoV-2 during the study were withdrawn from the study. During the trial, the investigator instructed the participants to undergo laboratory tests, including PCR, if the participant experienced fever, chills, cough, shortness of breath, and/or dyspnea for at least 24 hours or if the participant experienced malaise, myalgia, arthralgia, headache, dysgeusia, smell disorder, sore throat, stuffy nose, runny nose, nausea, vomiting, and diarrhea for at least 48 hours. This study was reviewed and approved by the institutional review boards (IRBs) of all the institutions. Written informed consent was obtained from all participants before the screening. In addition, the study was conducted in compliance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice (GCP) ordinance, etc., and registered in a jRCT at the initiation of the study (jRCT2071210081).

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

This study used KD-414 with 10 µg/dose of the active ingredients (converted to total protein amount) which was manufactured following good manufacturing practice (GMP) standards for investigational new drugs in Japan. A total of three vaccinations were administered for the primary series: two intramuscular vaccinations of KD-414 at an interval of 28 days followed by one intramuscular vaccination administered 13 weeks after the second vaccination. The original plan was to administer two doses at the start of this study. However, the plan was revised, and three doses were administered for the primary series during this study based on the results of the preceding phase 1/2 study. The change in the protocol was explained to all participants continuing on the study to obtain informed consent. The third vaccination was administered to participants who wished to receive the third vaccination among those who gave written informed consent. Each participant recorded his/her health status and body temperature in an e-diary during the period beginning after each vaccination with KD-414 to day six after vaccination (a total of seven days, including the day of vaccination). The participants underwent a follow-up examination 28 days after the third vaccination. After completion of the follow-up examination, the participants entered a oneyear follow-up period, participants who did not receive the second or third vaccination also entered a one-year follow-up period after the last vaccination. For immunogenicity evaluation, up to 100, 50, 50, 50, and 50 participants were allocated to the immunogenicity analysis subjects by age groups of 18 - 29 years, 30 - 39 years, 40 - 49 years, 50 - 59 years, and 60 years or older, respectively, in the order of enrollment at pre-specified medical institutions. In immunogenicity analysis subjects, blood was collected before and 28 days after each dose and 13, 26, and 52 weeks after the third dose to measure the neutralizing antibody titer against the pseudovirus SARS-CoV-2 (Wuhan). Injection site erythema, swelling, induration, and pain, which were observed after administration of each dose of KD-414 up to six days after vaccination, were defined as solicited local adverse events and were generally considered to be related to the investigational product. Fever, headache, malaise, nausea, and myalgia, which were observed after administration of each dose of KD-414 up to six days

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

172

after vaccination, were defined as solicited systemic adverse events. All events not that could not be characterized as solicited adverse events were recorded as unsolicited adverse events. Adverse events were classified into five grades (grades 0 to 4). The criteria were in accordance with those of the Food and Drug Administration (FDA) 14, however, erythema/redness, induration/swelling, and fever with a severity of less than grade 1 were characterized as grade 0. Among all adverse events, those for which there was at least a reasonable possibility of a relationship with the investigational product that could not be ruled out were defined as adverse reactions.

The primary endpoint was the geometric mean neutralizing antibody titers (GMTs) of KD-414 against the pseudovirus SARS-CoV-2 (Wuhan) 28 days after the second vaccination and third vaccinations, respectively. As a secondary endpoint, the neutralizing antibody-seroconversion rates 28 days after the second and third vaccination with the investigational product, respectively, were evaluated. The neutralizing antibody-seroconversion rate was defined as the rate of participants whose neutralizing antibody titer increased at least 4-fold compared to that before the first vaccination of the investigational product.

#### Pseudovirus SARS-CoV-2 (Wuhan) spike protein neutralizing antibody titers

The pseudovirus neutralizing antibody assay<sup>12</sup> was performed at LabCorp Drug Development. The pseudovirus neutralizing antibody assay with a lentivirus-based pseudovirus particle expressing the SARS-CoV-2 (Wuhan) spike protein was validated at Monogram Biosciences and then transferred to LabCorp Drug Development. Briefly the mixed pseudoviruses and serially diluted serum samples were incubated in HEK293 cells expressing the ACE2 receptor. After incubation, the luciferase produced was measured to determine the pseudovirus neutralizing antibody titers (50% inhibition dose [ID50]) using the following calculation formula. The lower limit of quantitation (LLOQ) for pseudovirus neutralizing antibodies was 40 (ID50).

171 % Inhibition = 100% – (((RLU (Vector + Sample + Diluent) –

RLU (Background)) / (RLU (Vector + Diluent) – RLU (Background))) × 100%)

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Statistical Analysis The target sample size for this study was set to 2000 participants to evaluate the safety profile of KD-414. Since this was an exploratory study, no hypothesis testing was performed with statistically powered sample sizes. Therefore, no adjustment for the multiplicity of type I errors was performed. In all the analyses, missing data were not imputed. Safety analyses were performed for the KD-414-vaccinated population with evaluable safety data. The number of participants and incidence of solicited local adverse reactions, solicited systemic adverse reactions, and unsolicited adverse reactions were calculated. Immunogenicity analysis was performed in the full analysis set (FAS) and per-protocol set (PPS). The results of the PPS analysis were handled as the primary results. The FAS involved the population of participants vaccinated with KD-414 among the immunogenicity analysis subjects, excluding those without data on neutralizing antibody titers after investigational product vaccination and those with deviation from GCP. PPS was defined as the population in which participants with major deviations from the protocol (related to the inclusion criteria, dosage and administration, prohibited concomitant medications/therapies, and timing of blood collection) were excluded from the FAS. For the primary evaluation, the GMTs were analyzed 28 days after the second and third vaccination, respectively, and the 95% CI was calculated based on the t-distribution. For the secondary evaluation, the seroconversion rate of the neutralizing antibody titer and the Clopper-Pearson 95% CI were calculated. In addition, subgroup analyses were performed according to the age group. For other demographic characteristics factors, descriptive statistics were calculated for continuous data, and the frequencies and the percentages were calculated for categorical data. SAS Release 9.4 (SAS Institute Inc., Cary, NC, USA) was used for the statistical analysis. **Results Population** 

While the target number of participants was 2000, 2500 participants received the first vaccination of

the investigational product, and 2474 participants received up to the second vaccination. A total of 150 participants discontinued the study after the second vaccination. Of these, 106 participants discontinued the study after they were confirmed to have been infected with SARS-CoV-2, according to the protocol. Written consent was obtained from 2324 participants for changes in protocol for the administration of additional third vaccination. The third vaccination was administered to 2081 participants who wished to receive the third vaccination. A total of 243 participants who did not wish to receive the third vaccination proceeded to the follow-up period after the second vaccination. Similarly, of the 295 participants in the immunogenicity analysis subjects, 291 participants received up to the second vaccination, and 249 participants received the third vaccination. None of the 2500 participants who received at least one dose of the investigational product were excluded from the safety set. Of the 295 participants in the immunogenicity analysis subjects, 292 participants were included in the FAS, of whom 287 participants were included in the PPS. (Figure 1)

The mean age of the participants in the safety analysis set was 43.2 years, with no particular preference for sex. The percentage of participants with the underlying diseases was 5.5%. The distributions of age, sex, and underlying diseases in the PPS were also similar. The percentage of participants with a negative neutralizing antibody titer against the pseudovirus SARS-CoV-2 before the first vaccination with the investigational product was 96.5%. (Table 1)

## Safety

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

No participants died. Four serious adverse events (SAE) other than death were observed in four participants during the period from after the first vaccination with the investigational product to 28 days after the second vaccination with the investigational product and the period from after the third vaccination to 28 days after the third vaccination. The investigator did not consider the SAE to be related to the investigational product. Nine events in seven participants required or should have led to discontinuation of the investigational product (significant adverse events). The investigator considered all significant adverse events related to the investigational product.

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

The incidence (number of participants with onset/number of participants in the safety analysis set) of adverse reactions from after the first vaccination to 28 days after the third vaccination of the investigational product in the safety analysis set, in which KD-414 was administered at least once, was 80.6% (2015/2500). The most common adverse reaction was injection site pain. Relatively common adverse reactions with an incidence of 10% or higher included injection site pain, malaise, headache, injection site erythema, myalgia, and injection site induration. When the incidence of adverse reactions was examined based on age, the incidence of solicited systemic adverse reactions was higher in participants aged 18 - 40 years than in participants aged 41 - 64 years or those aged 65 years or older. No noteworthy trends was observed in the incidence of adverse reactions in participants with or without underlying diseases. (Table 2) Eleven adverse reactions of high severity (grade 3 or higher) were observed in nine participants. Most adverse reactions were of grade 1 or 2. (Table 3) No differences were observed in the types of adverse reactions associated with first, second and third vaccinations, and no noteworthy tendency was observed with respect to the incidences. (Table 4) From the first vaccination with the investigational product to the completion of the follow-up examination, no case of suspected vaccine-associated enhanced respiratory disease (ERD) or antibody dependent enhancement (ADE) was reported. **Neutralizing responses** The GMTs (95% CI) for pseudovirus SARS-CoV-2 28 days after the second and third vaccination of the investigational product were 139.6 (118.9 - 164.0) and 285.6 (244.3 – 334.0), respectively, showing an approximately two-fold increase after the third vaccination compared to that after the second vaccination. The neutralizing antibody-seroconversion rates (95% CI) 28 days after the second and third vaccination were 67.0% (61.2% - 72.5%) and 84.5% (79.3% - 88.9%), respectively. (Table 5) Analyses of neutralization GMTs by age subgroups of 18 - 40 years, 41 - 64 years, and  $\geq$  65 years

showed that the values were 199.9 (163.6 - 244.4), 103.2 (79.9 - 133.2), and 50.7 (26.5 - 97.1), respectively, 28 days after the second vaccination, and 327.6 (269.8 – 397.9), 272.2 (211.5 - 350.4), and 128.0 (51.6 - 317.7), respectively, 28 days after the third vaccination. (Table 6)

## **Discussion**

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

When intramuscularly administered three times to healthy Japanese participants aged 18 years or older who had no history of both COVID-19 and COVID-19 vaccination including unapproved vaccines, a favorable safety profile of KD-414 (10 μg/dose) was shown. The neutralizing antibody titers against pseudovirus SARS-CoV-2 (Wuhan) increased after the third vaccination. The most frequent adverse reaction was injection site pain, followed by relatively frequent adverse reactions such as malaise, headache, injection site erythema, myalgia, and injection site induration. Most adverse reactions were characterized as grade 1 or 2. A total of 11 grade 3 adverse reactions that prevented daily activities were reported in nine participants, and nine adverse reactions that led to the discontinuation of the following vaccination were reported in seven participants. Many grade 3 adverse reactions and adverse reactions leading to discontinuation of the following vaccination have resolved or have become less severe, and some are still under the follow-up observation. No deaths or serious adverse events with causal relationships were reported. The incidences of solicited local adverse reactions and fever after the third vaccination with KD-414 were similar to those of approved inactivated vaccines used worldwide, mainly in China (BBIBP-CorV, CoronaVac) 15, 16, and suggesting that the incidence may be relatively lower than those of approved mRNA vaccines which are currently mainly being used in Japan (Comirnaty, Spikevax) 3,4, which were registered in the WHO Emergency Use Listing Procedure (EUL) 1. In addition, no noteworthy trends were observed in the types and incidences of adverse reactions depending on the number of vaccinations of KD-414. In case that periodical COVID-19 vaccinations will be needed in the future, it should be more favorable for public health to be able to choose useful vaccines produced by several modalities having the profiles like low incidence of adverse reactions and no increase of adverse reactions depending on number of dosing. Since the number of enrolled

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

participants with underlying diseases predetermined in this study protocol was small, further investigation on the safety profile of KD-414 in the specific population is necessary. Although the data is limited in this study, since no particular trend was observed in the incidence of adverse reactions depending on the presence or absence of underlying diseases, KD-414 is expected to be safe for that persons with underlying disease. Currently in Japan, only mRNA vaccine is available for children under five years of age. In addition, approved mRNA vaccines can be administered to pregnant women only when the benefits outweigh their risks. On the other hand, KD-414 has typically demonstrated relatively few adverse reactions, including those of grade 3 or higher. In this sense, KD-414 is expected to be more safely for children and pregnant women. In the future, it is necessary to evaluate safety of KD-414 in the aforementioned populations.

For immunogenicity, the product H (10 µg/dose) of KD-414 that induced the highest neutralizing antibody titers was selected for the subsequent phases based on the results after the second vaccination of KD-414 in the phase 1/2 study. However, although the preventive effect of the novel corona vaccine against the onset has been shown to correlate highly with the neutralizing antibody level, the threshold of the neutralizing antibody titers required for prevention has not yet been established. Therefore, it is important to evaluate the administration regimen of the three doses of KD-414, in which a higher neutralizing antibody titer can be expected. Therefore, the safety and immunogenicity of the three doses were evaluated in a phase 2/3 study using the administration method in which the third dose is administered three months after the second dose as the primary series. The results showed that GMTs increased by approximately two-folds 28 days after the third investigational product vaccination as compared with that 28 days after the second vaccination, and the extent of increase was similar to that observed after the third vaccination at 6 months after the second vaccination in the phase 1/2 study 12. The persistence of neutralizing antibody titers after the third vaccination is currently being evaluated in a phase 2/3 study. Analysis of GMTs by age group has shown that the tendency of reduction in the neutralizing antibody titers in the elderly was observed with KD-414, similar to the previously approved vaccines for SARS-CoV-2 17, 18.

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

Currently, no surrogate marker has been established to evaluate the vaccine efficacy against COVID-19, and the method of measurement of neutralizing antibody titers differs among studies. Therefore, it is difficult to directly compare its efficacy with that of other vaccines. With reference to the literature that reported the vaccine efficacy (VE) of Vaxzevria (the active comparator in the currently ongoing pivotal phase 3 study examining KD-414) against the original strain, which was estimated from the neutralizing antibody titer level <sup>19</sup>, we obtained the international standard units (IU) converted value of neutralization GMTs against pseudovirus SARS-CoV-2 (Wuhan) using the same method as in the literature, and attempted to estimate the VE of KD-414 against the original strain of SARS-CoV-2 after vaccination. The results shows that the KD-414 IU converted values of GMTs after the second and third vaccination in participants aged 18 - 40 years were 29.1 IU/mL and 47.8 IU/mL, respectively (Table 6). VE was estimated to be about 70% to 80%, respectively, suggesting that the efficacy of KD-414 could be comparable to that of the approved vaccines. In the future, based on the idea of rebalancing proposed by ICMRA <sup>20</sup>, the efficacy of KD-414 is planned to be confirmed by verifying the superiority of immunogenicity to that of Vaxzevria in the ongoing pivotal phase 3 study. In addition, it is necessary to examine the cross-reactivity of neutralizing antibody responses elicited by KD-414 vaccination against SARS-CoV-2 variants, and SARS-CoV-2 -specific cellular immune response. As a limitation of this study, the elevation of antibody titers as a results of asymptomatic infection was not fully excluded under the COVID-19 outbreak status. In addition, the cellular immune response by KD-414 vaccination will be evaluated in the currently ongoing phase 3 study in due course. The cross-reactivity of neutralizing antibody responses to SARS-CoV-2 variants and the incidence rate of COVID-19 infection after KD-414 dosing are currently being accumulated. The aforementioned reports support the progress of the next phase of clinical studies on KD-414. The three-dose regimen with KD-414 as the primary vaccination is expected to provide good safety and induce high neutralizing antibody titers, especially in the age group of 18 to 40 years. Currently, phase

3 (jRCT2031210679) trial with adults aged 18 to 40 years is ongoing to verify the efficacy of three vaccinations with KD-414 as the primary vaccination. In addition, a phase 2/3 study (jRCT2031220032) in children aged  $\geq 6$  months to  $\leq 18$  years is ongoing to evaluate the safety and immunogenicity of KD-414.

335

336

337

338

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

ACKNOWLEDGEMENT This study was funded by Japan Agency for Medical Research and Development (21nf0101622h0002) and Pharmaceutical Development Support Center. We thank the Institute of Medical Science, the University of Tokyo which provided a virus strain (SARS-CoV-2/UT-HPCo-038/Human/2020/Tokyo). We also thank all the participants who volunteered for this study. **AUTHOR CONTRIBUTIONS** KK, KI, MT, and YM designed and coordinated this clinical trial. HN and YO advised technical expertise. KS and ME managed the investigational drug manufacturing and the neutralizing antibody assay. SN, KH, KA, YS, and YI managed and analyzed the data of this study. KU contributed to the clinical trial as a medical expert. KK wrote the first draft manuscript, and YS and TM wrote, reviewed and edited. All authors reviewed and approved the final version. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. **CONFLICT OF INTEREST** All authors, except for Yuji Sasagawa, Yasuhiro Iwama, and Kohji Ueda, are employees of KM Biologics Co., Ltd. Yuji Sasagawa and Yasuhiro Iwama are employees of Meiji Seika Pharma Co., Ltd., co-developer of KD-414. Kohji Ueda received a fee from KM Biologics Co., Ltd., for the implementation of this study.


## References

- 363 WHO Emergency use listing (EUL) / Covid-19 Vaccines.
- 364 https://www.who.int/teams/regulation-prequalification/eul/covid-19 (accessed Sep 21, 2022).
- 365 World Health Organization. WHO coronavirus disease (COVID-19) dashboard.
- 366 https://covid19.who.int/ (accessed Sep 21, 2022).
- 367 Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2
- 368 vaccine. N Engl J Med 2021; 384: 403-16.
- 369 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19
- 370 vaccine. N Engl J Med 2020; 383: 2603-15.
- 371 Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 5.
- 372 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled
- 373 trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99-111.
- 374 Janssen Biotech. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA briefing
- 375 document. Presented at the Vaccines and Related Biological Products Advisory Committee
- 376 Meeting, February 26, 2021 (https://www.fda.gov/media/146217/download).
- 377 7. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the
- 378 United States and Mexico. N Engl J Med 2022; 386: 531-43.
- 379 Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA COVID-
- 380 19 Vaccination. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html.
- 381 (accessed Sep 21, 2022).
- 382 Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of
- 383 Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-
- 384 19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on
- 385 Immunization Practices — United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021
- 386 Aug 13; 70(32): 1094-99.
- 387 10. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1
- 388 nCov-19 Vaccination. N Engl J Med 2021; 384: 2092-2101.

- 389 11. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after
- 390 ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384: 2124-30.
- 391 12. Tanishima M, Ibaragi K, Kido K, et al. Safety and immunogenicity of an inactivated SARS-
- CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, 392
- 393 placebo-controlled, phase 1/2 clinical study in Japan. medRxiv 2022 Jun.
- 394 13. David SK, Deborah C, Arnold R, et al. Neutralizing antibody levels are highly predictive of
- 395 immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021 Jul; 27:
- 396 1205-11.
- 397 14. U.S. Department of Health and Human Services Food and Drug Administration Center for
- 398 Biologics Evaluation and Research. Guidance for Industry Toxicity Grading Scale for Healthy
- 399 Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. September
- 400 2007.
- 401 15. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2
- 402 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet
- 403 Infect Dis 2020; 21: 39-51.
- 404 16. Zhang, Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated
- 405 SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-
- 406 controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181-92.
- 407 17. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019
- 408 Vaccination. Clin Infect Dis 2021; 73, 2065-72.
- 409 18. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the Corona Vac vaccine in older
- 410 adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-
- 411 control study. BMJ 2021; 374, n2015.
- 412 19. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- 413 asymptomatic SARS-CoV-2 infection. Nature Medicine 2021; 27: 2032-40.
- 414 20. International Coalition of Medicines Regulatory Authorities. ICMRA COVID-19 Vaccine
- 415 Development: Future Steps Workshop. June 2021. Available online:

416 http://www.icmra.info/drupal/en/covid-19/24june2021 (accessed Sep 21, 2022).

#### Figure 1: Trial profile



# Table 1: Characteristics of the Participants

423

424

425

426

427

Characteristic	Safety analysis set (N=2500)	Per protocol set (N=287)
Age, years	43.2(11.9)	41.0(14.7)
18-40 years	1005(40.2)	148(51.6)
40-64 years	1427(57.1)	125(43.6)
≥65 years	68(2.7)	14(4.9)
Sex		
Male	1200(48.0)	144(50.2)
Female	1300(52.0)	143(49.8)
Underlying disease		
With	2363(94.5)	269(93.7)
Without	137(5.5)	18(6.3)
Baseline anti-SARS CoV-	2 neutralizing antibody	
Negative	NA	277(96.5)
Positive	NA	10(3.5)

Data are mean(SD) or n(%).

Underlying disease: such as cardiovascular diseases, renal diseases, hepatic diseases, hematological diseases, developmental disorders, respiratory diseases, or diabetes mellitus.

Table 2: Adverse reactions within 7 days after the first, second, or third doses.

						-											
429	Data a Underl disord	Mus	Nausea	Fatigue	Hea	Fever	Any	Solicit	Pain	Indu	Swe	Ery	Any	Solicit	Any a		
430	are n(% lying d ers, re	Muscle pain	Isea	gue	Headache	er		ed syst	_	Induration	Swelling	Erythema		ed Inje	Any adverse reaction		
431	), repr isease: spirato	<del> </del>						lemic a						ction s	reactio		
432	esentin such a y disea							dverse						ite adve	'n		
433	ig the t as card ases, d							reacti						erse re			
434	otal nu liovasc or diabe	3(	_	63	47	"	96	ons wit	18	26	2	4(	18	actions	20	<b>a</b>	
435	Data are n(%), representing the total number of par Underlying disease: such as cardiovascular disease disorders, respiratory diseases, or diabetes mellitus	300(12.0)	108(4.3)	634(25.4)	470(18.8)	99(4.0)	964(38.6)	Solicited systemic adverse reactions within 7 days	1810(72.4)	261(10.4)	233(9.3)	407(16.3)	1870(74.8)	within	2015(80.6)	(N=2500)	
436	Data are n(%), representing the total number of participants who had adverse reactions related to vaccination. Underlying disease: such as cardiovascular diseases, renal diseases, hepatic diseases, hematological diseases, developmental disorders, respiratory diseases, or diabetes mellitus.	٥			٣		٥	ays	<b>±</b>			٣	33	Solicited Injection site adverse reactions within 7 days	3)	٠	ı
437	ipants , renal													U)			
438	who hadisease	129(12.8)	56(5.6)	299(29.8)	232(23.1)	65(6.5)	451(44.9)		760(75.6)	81(8.1)	78(7.8)	135(13.4)	774(77.0)		_	18-40 years (N=1005)	
439	ad advo	2.8)	6)	9.8)	3.1)	5)	4.9)		5.6)	<u></u>	8)	3.4)	7.0)			/ears 105)	
440	erse re eatic di																
441	actions seases	166	52	323	232	32	493		101,	172	152	266	105			41-6 <sub>-</sub> (N=	1
442	relate, hema	166(11.6)	52(3.6)	323(22.6)	232(16.3)	32(2.2)	493(34.5)		1014(71.1)	172(12.1)	152(10.7)	266(18.6)	1057(74.1)		1	41-64 years (N=1427)	Age
443	d to va tologica															9,	
444	ccinational disea			_					(.)				(.)			ı⊻	
445	on. ases, c	5(7.4)	0(0.0)	12(17.6)	6(8.8)	2(2.9)	20(29.4)		36(52.9)	8(11.8)	3(4.4)	6(8.8)	39(57.4)		-	≥65 years (N=68)	
446	levelopi						)		)							rs	
447	mental			_					_				_			_	
448		277(11.7)	102(4.3)	601(25.4)	445(18.8)	96(4.1)	907(38.4)		1727(73.1)	245(10.4)	218(9.2)	391(16.5)	1781(75.4)		-	With (N=2363)	U
449		.7)	3)	.4)	.8)	_	.4)		3.1)	.4)	2)	.5)	5.4)			3)	nderlyi
450																	Underlying disease
451		23(16.8)	6(4.4)	33(24.1)	25(18.2)	3(2.2)	57(41.6)		83(60.6)	16(11.7)	15(10.9)	16(11.7)	89(65.0)		,	Without (N=137)	ase
452		8)	٣	1	2)	۳	6)		6)	.7)	9)	7)	0)			out (7)	

## Table 3: Severity of Adverse reactions within 7 days after the first, second, or third doses.

455

456

457

458

459

460

Overall(N=2500)	Grade 0	Grade 1	Grade 2	Grade 3
Solicited Injection site	adverse reactions w	vithin 7 days		
Any	54(2.2)	1729(69.2)	86(3.4)	1(0.0)
Erythema	392(15.7)	12(0.5)	3(0.1)	0(0.0)
Swelling	182(7.3)	44(1.8)	7(0.3)	0(0.0)
Induration	216(8.6)	37(1.5)	8(0.3)	0(0.0)
Pain	NA	1735(69.4)	74(3.0)	1(0.0)
Solicited systemic adve	erse reactions within	n 7 days		
Any	22(0.9)	827(33.1)	108(4.3)	7(0.3)
Fever	79(3.2)	13(0.5)	5(0.2)	2(0.1)
Headache	NA	421(16.8)	47(1.9)	2(0.1)
Fatigue	NA	563(22.5)	68(2.7)	3(0.1)
Nausea	NA	98(3.9)	9(0.4)	1(0.0)
Muscle pain	NA	282(11.3)	17(0.7)	1(0.0)

Data are n/N(%), representing the total number of participants who had adverse reactions related

The severity of adverse events were graded as Grade0, Grade1 (Mild), Grade2 (Moderate), Grade3 (Severe), and Grade4 (Potentially life threatening).

# Table 4: Solicited and unsolicited adverse reactions within 7 days after each dose.

	After 1st dose	After 2 <sup>nd</sup> dose	After 3 <sup>rd</sup> dose
	(N=2500)	(N=2474)	(N=2081)
Solicited Injection sit	te adverse reactions withir	n 7 days	
Any	1344(53.8)	1407(56.9)	1109(53.3)
Erythema	178(7.1)	214(8.6)	201(9.7)
Swelling	65(2.6)	112(4.5)	115(5.5)
Induration	84(3.4)	125(5.1)	123(5.9)
Pain	1266(50.6)	1346(54.4)	1039(49.9)
Solicited systemic ad	dverse reactions within 7 d	days	
Any	563(22.5)	526(21.3)	393(18.9)
Fever	43(1.7)	38(1.5)	33(1.6)
Headache	243(9.7)	243(9.8)	159(7.6)
Fatigue	351(14.0)	319(12.9)	269(12.9)
Nausea	48(1.9)	50(2.0)	30(1.4)
Muscle pain	160(6.4)	123(5.0)	90(4.3)
Unsolicited systemic	adverse reactions within	28 days	
Any	294(11.8)	225(9.1)	147(7.1)

Data are n(%), representing the total number of participants who had adverse reactions related to vaccination.

## Table 5: Geometric mean titers and seroconversion rate to SARS-CoV-2 (Wuhan) pseudovirus

## induced before first dose and after each dose of KD-414.

SARS-CoV-2 (Wuhan) ps	seudovirus	neutralizing antibody titer		
Time Point	n	GMT (ID50)	Seroconversion	GMT(IU/mL)
Before 1st dose	287	21.7[20.6-22.8]	NA	-
Day 28 after 1st dose	287	26.8[24.3-29.6]	6.6%[4.0-10.1%]	-
Day 28 after 2 <sup>nd</sup> dose	282	139.6[118.9-164.0]	67.0%[61.2-72.5%]	20.4[17.3-23.9]
Day 28 after 3 <sup>rd</sup> dose	239	285.6[244.3-334.0]	84.5%[79.3-88.9%]	41.6[35.6-48.7]

Geometric mean titers are shown with 95%CI. Seroconversion rates are n/N(%[95%CI]).

The ID<sub>50</sub> GMTs were converted to the WHO international standard units (IU/mL) using the conversion factor "0.1458 (for geometric mean)" determined with the WHO International Standard (20/136).

Seroconversion was defined as four-fold titer increase from baseline.

Table 6: Geometric mean titers, seroconversion rate, and geometric mean titers converted to the

WHO international standard units (IU/mL) induced after second and third doses of KD-414.

The ID-: GMTs were converted to	The ID., CMTs, were converted to the WIAO international standard units (III/m) I using the conversion factor "0 1458 (for geometric mean
Standard (20/136).	
Seroconversion was defined as f	nversion was defined as four-fold titer increase from baseline.

		De	Day 28 after 2 <sup>nd</sup> dose			Di	Day 28 after 3 <sup>rd</sup> dose	
	п	GMT (ID50)	Seroconversion rate	GMT (IU/mL)	n	GMT (ID50)	Seroconversion rate	GMT (IU/mL)
18-40 years	144	199.9[163.6-244.4]	80.6%[73.1-86.7%]	29.1[23.8-35.6]	119	327.6[269.8-397.9]	90.8%[84.1-95.3%]	47.8[39.3-58.0]
41-64 years	124	103.2[79.9-133.2]	54.8%[45.7-63.8%]	15.0[11.6-19.4]	106	272.2[211.5-350.4]	80.2%[71.3-87.3%]	39.7[30.8-51.1]
≥65 years	14	50.7[26.5-97.1]	35.7%[12.8-64.9%]	7.4[3.9-14.2]	14	128.0[51.6-317.7]	64.3%[35.1-87.2%]	18.7[7.5-46.3]
Geometric mean to	an titers were c	are shown with 95%CI.	Geometric mean titers are shown with 95%CI. Seroconversion rates are n/N(%[95%CI]). The ID <sub>50</sub> GMTs were converted to the WHO international standard units (IU/mL) using the	Geometric mean titers are shown with 95%CI. Seroconversion rates are n/N(%[95%CI]).  The ID <sub>50</sub> GMTs were converted to the WHO international standard units (IU/mL) using the conversion factor "0.1458 (for geometric mean)" determined with the WHO International	on factor "C	.1458 (for geometric me	an)" determined with the V	NHO International